Influence of agonist intrinsic activity on the desensitisation of β 2-adrenoceptor-mediated responses in mast cells

Anne Marie Scola, Lee K. Chong, Rusell Chess-Williams, Peter T. Peachell

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

1 The aim of the present study was to determine whether the intrinsic activity of an agonist influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in human lung mast cells. 2 The effects of a wide range of β-adrenoceptor agonists (10 -10-10 -5 M) on the IgE-mediated release of histamine from mast cells were determined. The intrinsic activity of agonists was established by comparing the maximal inhibitory response (E max) of an agonist relative to the maximal response obtained with the full agonist, isoprenaline. The intrinsic activity order for the inhibition of histamine release was isoprenaline (1.0) > formoterol (0.94) > fenoterol (0.89) > terbutaline (0.84) > salbutamol (0.69) > clenbuterol (0.65) > salmeterol (0.30) > dobutamine (0.20). 3 There was a significant (P < 0.05) positive correlation (r = 0.81) between the extent to which β-adrenoceptor agonists inhibited histamine release and the degree to which the agonists caused elevations in cAMP in mast cells. 4 Further studies investigated the effects of long-term (24 h) incubation of mast cells with β-adrenoceptor agonists on the subsequent ability of isoprenaline to inhibit histamine release. At concentrations of agonists selected to occupy a large percentage (88%) of β 2-adrenoceptors, there was a significant (P < 0.05) correlation (r = 0.73) between the relative intrinsic activity of agonists as inhibitors of histamine release and the extent of functional desensitisation induced by the agonists. At lower receptor occupancies, however, there was no correlation between the relative intrinsic activity of agonists and the extent of agonist-induced desensitisation. 5 These data indicate that, under experimental conditions where high receptor occupancies prevail, agonist intrinsic activity influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in mast cells.

Original languageEnglish
Pages (from-to)71-80
Number of pages10
JournalBritish Journal of Pharmacology
Volume143
Issue number1
DOIs
Publication statusPublished - Sep 2004
Externally publishedYes

Fingerprint

Mast Cells
Histamine Release
Adrenergic Receptors
Isoproterenol
Clenbuterol
Fenoterol
Terbutaline
Dobutamine
Albuterol
Immunoglobulin E
Lung

Cite this

@article{29b24de0f73f4b4c9650c2aa6e726af2,
title = "Influence of agonist intrinsic activity on the desensitisation of β 2-adrenoceptor-mediated responses in mast cells",
abstract = "1 The aim of the present study was to determine whether the intrinsic activity of an agonist influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in human lung mast cells. 2 The effects of a wide range of β-adrenoceptor agonists (10 -10-10 -5 M) on the IgE-mediated release of histamine from mast cells were determined. The intrinsic activity of agonists was established by comparing the maximal inhibitory response (E max) of an agonist relative to the maximal response obtained with the full agonist, isoprenaline. The intrinsic activity order for the inhibition of histamine release was isoprenaline (1.0) > formoterol (0.94) > fenoterol (0.89) > terbutaline (0.84) > salbutamol (0.69) > clenbuterol (0.65) > salmeterol (0.30) > dobutamine (0.20). 3 There was a significant (P < 0.05) positive correlation (r = 0.81) between the extent to which β-adrenoceptor agonists inhibited histamine release and the degree to which the agonists caused elevations in cAMP in mast cells. 4 Further studies investigated the effects of long-term (24 h) incubation of mast cells with β-adrenoceptor agonists on the subsequent ability of isoprenaline to inhibit histamine release. At concentrations of agonists selected to occupy a large percentage (88{\%}) of β 2-adrenoceptors, there was a significant (P < 0.05) correlation (r = 0.73) between the relative intrinsic activity of agonists as inhibitors of histamine release and the extent of functional desensitisation induced by the agonists. At lower receptor occupancies, however, there was no correlation between the relative intrinsic activity of agonists and the extent of agonist-induced desensitisation. 5 These data indicate that, under experimental conditions where high receptor occupancies prevail, agonist intrinsic activity influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in mast cells.",
author = "Scola, {Anne Marie} and Chong, {Lee K.} and Rusell Chess-Williams and Peachell, {Peter T.}",
year = "2004",
month = "9",
doi = "10.1038/sj.bjp.0705905",
language = "English",
volume = "143",
pages = "71--80",
journal = "British journal of pharmacology and chemotherapy",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

Influence of agonist intrinsic activity on the desensitisation of β 2-adrenoceptor-mediated responses in mast cells. / Scola, Anne Marie; Chong, Lee K.; Chess-Williams, Rusell; Peachell, Peter T.

In: British Journal of Pharmacology, Vol. 143, No. 1, 09.2004, p. 71-80.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Influence of agonist intrinsic activity on the desensitisation of β 2-adrenoceptor-mediated responses in mast cells

AU - Scola, Anne Marie

AU - Chong, Lee K.

AU - Chess-Williams, Rusell

AU - Peachell, Peter T.

PY - 2004/9

Y1 - 2004/9

N2 - 1 The aim of the present study was to determine whether the intrinsic activity of an agonist influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in human lung mast cells. 2 The effects of a wide range of β-adrenoceptor agonists (10 -10-10 -5 M) on the IgE-mediated release of histamine from mast cells were determined. The intrinsic activity of agonists was established by comparing the maximal inhibitory response (E max) of an agonist relative to the maximal response obtained with the full agonist, isoprenaline. The intrinsic activity order for the inhibition of histamine release was isoprenaline (1.0) > formoterol (0.94) > fenoterol (0.89) > terbutaline (0.84) > salbutamol (0.69) > clenbuterol (0.65) > salmeterol (0.30) > dobutamine (0.20). 3 There was a significant (P < 0.05) positive correlation (r = 0.81) between the extent to which β-adrenoceptor agonists inhibited histamine release and the degree to which the agonists caused elevations in cAMP in mast cells. 4 Further studies investigated the effects of long-term (24 h) incubation of mast cells with β-adrenoceptor agonists on the subsequent ability of isoprenaline to inhibit histamine release. At concentrations of agonists selected to occupy a large percentage (88%) of β 2-adrenoceptors, there was a significant (P < 0.05) correlation (r = 0.73) between the relative intrinsic activity of agonists as inhibitors of histamine release and the extent of functional desensitisation induced by the agonists. At lower receptor occupancies, however, there was no correlation between the relative intrinsic activity of agonists and the extent of agonist-induced desensitisation. 5 These data indicate that, under experimental conditions where high receptor occupancies prevail, agonist intrinsic activity influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in mast cells.

AB - 1 The aim of the present study was to determine whether the intrinsic activity of an agonist influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in human lung mast cells. 2 The effects of a wide range of β-adrenoceptor agonists (10 -10-10 -5 M) on the IgE-mediated release of histamine from mast cells were determined. The intrinsic activity of agonists was established by comparing the maximal inhibitory response (E max) of an agonist relative to the maximal response obtained with the full agonist, isoprenaline. The intrinsic activity order for the inhibition of histamine release was isoprenaline (1.0) > formoterol (0.94) > fenoterol (0.89) > terbutaline (0.84) > salbutamol (0.69) > clenbuterol (0.65) > salmeterol (0.30) > dobutamine (0.20). 3 There was a significant (P < 0.05) positive correlation (r = 0.81) between the extent to which β-adrenoceptor agonists inhibited histamine release and the degree to which the agonists caused elevations in cAMP in mast cells. 4 Further studies investigated the effects of long-term (24 h) incubation of mast cells with β-adrenoceptor agonists on the subsequent ability of isoprenaline to inhibit histamine release. At concentrations of agonists selected to occupy a large percentage (88%) of β 2-adrenoceptors, there was a significant (P < 0.05) correlation (r = 0.73) between the relative intrinsic activity of agonists as inhibitors of histamine release and the extent of functional desensitisation induced by the agonists. At lower receptor occupancies, however, there was no correlation between the relative intrinsic activity of agonists and the extent of agonist-induced desensitisation. 5 These data indicate that, under experimental conditions where high receptor occupancies prevail, agonist intrinsic activity influences the extent of desensitisation of β 2-adrenoceptor-mediated responses in mast cells.

UR - http://www.scopus.com/inward/record.url?scp=4644239557&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705905

DO - 10.1038/sj.bjp.0705905

M3 - Article

VL - 143

SP - 71

EP - 80

JO - British journal of pharmacology and chemotherapy

JF - British journal of pharmacology and chemotherapy

SN - 0007-1188

IS - 1

ER -